An evaluation of netilmicin, 150 mg BID, in systemic infections

The efficacy and tolerance of netilmicin administered in a simplified dosage schedule (150 mg BID) were evaluated in an open study of 20 patients with acute systemic infections. Duration of therapy ranged from 6 to 11 days. All isolated causative organisms were eradicated; 85% (17/20) of the patients experienced complete clinical resolution, and the remaining 15% (3/20) experienced definite improvement. No patients developed nephrotoxicity of ototoxicity. The results of this study demonstrate that netilmicin is both effective in the treatment of serious systemic infections and well tolerated when administered at 150 mg twice daily.